Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women. Bremelanotide does not interact with alcohol. The mechanism by which bremelanotide's action on... The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.
- Mechanism
- Curator reviewed · 4 references
Bremelanotide is an agonist of many melanocortin receptors which in order of potency are MC1R, MC4R, MC3R, MC5R, and MC2R. The mechanism by which agonism of these receptors translates to an improvement in hypoactive sexual desire disorder is currently unknown, however MC4R receptors are present in many areas of the central nervous system. MC3R and MC4R are found in the hypothalamus and are involved in food intake and energy homeostasis.
One theory is that bremelanotide stimulates dopamine in the medial preoptic area, which is involved in the sexual behaviour of a number of organisms.
- Primary indication
- Bremelanotide is indicated to treat premenopausal women with hypoactive sexual desire disorder that is not due to a medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug.Curator reviewed · 1 structured indication
- First approval
- United States, 2019
- Code names
- PT-141
- Brand names
Resolves to
What you can answer from here — as of September 23, 2026
Which drugs share a target with Bremelanotide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account